United States: OIG Will Not Impose Sanctions On Entities For Program That Provides Free Drugs To Patients Experiencing Delayed Insurance Approvals

On August 5, 2015, the Department of Health and Human Services ("HHS") Office of Inspector General ("OIG) issued  Advisory Opinion No. 15-11 (the "Opinion")1 in response to a request by pharmaceutical manufacturers that co-promote a drug and have implemented a program that provides the drug at no cost for a limited time to patients experiencing a delay in the insurance approval process (the "Program"). The OIG concluded that it would not impose administrative sanctions under its exclusion or civil money penalty authority based on kickback and beneficiary inducement theories.2

In this Client Alert, we provide a brief summary of the Program and the OIG's analysis. We then discuss the importance and potential implications of the Opinion to drug manufacturers introducing new drugs in the marketplace, and some of the key variables that should be considered when evaluating similar programs.

The Proposed Program The Food and Drug Administration ("FDA") approved the antineoplastic drug at issue through the fast-track process under its Breakthrough Therapy Designation process for certain indications, and to treat patients with specific types of cancer.3 In describing the relevant characteristics of the drug, the OIG noted that it is the sole approved product within some indications, but subject to competition from off-label agents with boxed warnings, and that a patient can switch from the drug to another therapy within a short period of time (only a two-day gap) and will see a response within two months of first using the drug. Further, patients can only obtain the drug through specialty pharmacies.

Patients must meet certain eligibility criteria to enroll in the Program, which is managed by the requestors, a vendor, and the vendor's affiliated pharmacy (the "Pharmacy"). To enroll, the patient must: (1) be a new patient; (2) have received a prescription for the drug; (3) have an on-label diagnosis; (4) be insured by a private or public payor; and (5) have experienced a delay in a coverage determination of five or more business days. Generally, the prescriber or pharmacy may submit a request to the Pharmacy for the drug under this Program if the patient or prescriber does not receive a decision from an insurer within five business days. This request to the Pharmacy must be through a separate prescription from the original prescriber. Thereafter, the Pharmacy dispenses up to two free, 30-day supplies of the drug to the patient.4 The patient is only eligible for a second 30-day supply if the coverage determination delay continues beyond the first 30-day period. To the extent that the patient continues to need the product (e.g., after insurance coverage has been secured), those follow-on prescriptions must be filled through a different specialty pharmacy.

The requestors and the OIG specifically addressed the application of the Program to Medicare Part D beneficiaries to pinpoint any additional risks associated with the Program, and the free supply provided to federal health care program ("FHCP") beneficiaries. The requestors stated that the Program is available to Medicare Part D or other FHCP beneficiaries in the event that they encounter coverage determination delays. However, they do not foresee many beneficiaries using the Program because of Medicare Part D's formulary and turn-around-time requirements (i.e., many antineoplastic drugs are required to be on the formularies, and plans are required to deliver coverage determinations within 72 hours).5 In fact, the requestors stated that the Program is used infrequently (representing only about .0008 percent of all dispensing), and only about one-third of all shipments of the drug under the Program have been to Medicare and Medicaid beneficiaries. Regardless, the requestors implemented certain protections, including that the Pharmacy must notify the patient's Part D plan sponsor if the drug is provided through the Program, and that no part of the costs should be counted toward the patient's true-out-of-pocket ("TrOOP") costs, and no claim should be submitted to the Part D plan sponsor for the free drug supply. Additionally, eligibility and receipt of the drug is not dependent upon future purchases of the drug or any other products manufactured by the requestors. In fact, those who continue to use the drug may be responsible for significant cost-sharing amounts unless the patient is receiving support through a patient assistance program. However, the requestors stated that they have not dispensed the drug to a patient who is enrolled in a separate patient assistance program that provides co-payment support for the same diseases.

Finally, although the manufacturers include information concerning the Program on company websites and in physician detailing materials, they do not advertise it in direct-to-patient communications.

The OIG's Analysis Because FHCP beneficiaries are receiving some of the free drug supplies under the Program, the OIG completed a two-part analysis for any implications under both the anti-kickback statute and the Beneficiary Inducements Civil Monetary Penalty Law ("Beneficiary Inducements CMP Law").

a. Anti-Kickback Statute The OIG concluded that the Program raises low risks under the anti-kickback statute, citing several factors:

1. Low Risk of Overutilization: The potential for overutilization is low because (a) the patient is not eligible for the Program if the insurer makes a favorable coverage decision within five business days; (b) the drug only treats certain types of cancer and the Program is restricted to on-label uses of the drug; and (c) the patient is only eligible for up to two, 30-day supplies of the drug.

2. It Is Not a Seeding Program: The OIG stated that this Program is different from a "seeding" program (i.e., where a manufacturer offers a drug for free or at a substantial discount to induce the patient to use the drug in the future), in that (a) the Program is not marketed directly to patients, (b) only a small percentage of the drug has been shipped under the Program, implying that patients and prescribers "assume" that it will be covered under insurance with the applicable cost-sharing amounts; and (c) it is only applicable in rare cases so it is unlikely to influence patients and prescribers to choose the drug over alternative therapies.

3. Prescribers Do Not Receive a Financial Benefit: The drug is dispensed directly to the patient from the Pharmacy, so prescribers do not receive any type of administrative fee for the drug.

4. There is a Limited Relationship Between the Pharmacy and Patient: The Pharmacy's role outside of the Program is limited because a patient who receives a free supply and possible refill under the program cannot obtain future refills from the Pharmacy. Further, the Pharmacy only dispenses to certain client programs so "it is unlikely that the [Program] would induce the patient to obtain other federally reimbursable drugs from the Pharmacy."

5. FHCPs Are Not Billed for the Free Supply: There is no cost to the FHCP for the free drug supply. Also, as previously noted, the claims are not submitted to Medicare Part D plan sponsors for the free supply or refill of the drug, and none of the costs for providing the drug under the Program should be accounted for in the patient's TrOOP.

b. Beneficiary Inducements CMP Law Similarly, the OIG concluded that it would not subject the requestors to sanctions under the Beneficiary Inducements CMP Law because there is a low risk that the Program would "influence the beneficiary's selection of a particular provider, practitioner, or supplier of any item or service for which payment may be made, in whole or in part, by Medicare [or another FHCP]." First, pharmaceutical manufacturers are not considered to be "providers, practitioners, or suppliers" under this law, as the OIG has stated in previous guidance, and thus the statute does not apply to potential incentives to select a product.6 Second, while the Pharmacy could be a "supplier," it will not dispense the product commercially outside of the Program under the limited business model (i.e., it only services certain client programs and not the general public, and it does not bill payors) and client base (i.e., only those that are eligible for similar client programs).

Discussion and Commentary As pharmaceutical manufacturers introduce new, more expensive, and more clinically complicated therapies into an increasingly regulated and competitive payor environment, the reimbursement challenges associated with those therapies can be critical inhibitors of patient access and, ultimately, commercial success. Viewed against that backdrop, Advisory Opinion 15-11 must be considered a net positive in that it confirms the important principle that free product starter programs pending insurance coverage determinations can be a legitimate mechanism to facilitate patient access to therapies under the right circumstances.

As with all advisory opinions, however, the OIG's views are limited to the requesting parties and the specifics of the proposed arrangement, and thus, the challenge for manufacturers, their distribution partners, and their advisors is to assess how the opinion may apply to slightly different circumstances. That is especially important to remember with Advisory Opinion 15-11, as there are at least a half-dozen variables in the fact pattern that could fairly be construed as potentially material to the analysis. Some potentially important areas of variation in other programs that should be considered may include:

  • Nature of the Product Several characteristics of the product in question strike us as potentially meaningful. First, the product is a rapid-response oncology product designated as a breakthrough therapy, which is significant because of (1) the potential clinical benefit to patients, (2) the likelihood that the patient would truly need the product, and (3) the broad coverage mandate for such products under Medicare Part D. Second, it lacks on-label competitors. Third, if coverage were ultimately denied, the patient could discontinue therapy without expected clinical consequences. This may very well be the most conservative product profile that could be envisioned from an analytical perspective.
  • Timing Triggers and Duration of Assistance The Program under review provided for assistance to begin after five days without a prior authorization determination, and that assistance could last up to 60 days. The former number suggests an important principle: that the coverage process should be given a fair chance to work, given the nature of the product, so that starting a patient on therapy does not completely circumvent legitimate utilization controls of the payor. At the same time, the latter number reflects an equally fair principle that those processes do not always work like clockwork, and that it is reasonable to provide for that. Whether either period may be longer or shorter may depend on the circumstances of the product and the expected coverage environment.
  • Limited Role of the Fulfillment Pharmacy The OIG emphasized the fact that the Program would not be an inducement to use the fulfillment Pharmacy for federally covered refills since the fulfillment Pharmacy did not otherwise dispense the product commercially, and that it would not be an inducement to the pharmacy to influence product selection for similar reasons. This strikes us as a no-brainer. But other scenarios could also entail low risks, such as if patients were referred for refills to a specialty pharmacy network, including the fulfillment pharmacy, on a neutral basis, or if the product were distributed exclusively through a single specialty pharmacy that also provided fulfillment functions.
  • Marketing the Program From our perspective, the OIG drew a fairly reasonable line between the dissemination of information about the Program to professionals or through the company's website on the one hand, and through other types of direct-to-consumer promotion on the other. While there are inherent limits on patients' ability to influence the use of prescription products, avoiding even this limited potential by restricting program communications to vehicles that are not overt patient-selling vehicles is a favorable factor for the anti-kickback analysis.
  • Scope of the Program The OIG noted that the Program dispensing represented only 0.0008 percent of all product utilization, which of course underscores that the Program was already in operation. While the OIG fairly points out that this limited scope may imply that providers expect a product to be covered, one would hope that the fact that a program is perceived to be unnecessary has not become the key decisional touchstone. Indeed, the time when such programs may be most important for facilitating patients' access to breakthrough therapies is when a product is new and the rules and logistics of coverage are most uncertain. In any event, it is impossible to know such utilization figures prospectively with any certainty, and so it is somewhat difficult to determine what to make of this factor from a counseling perspective.
  • New Patients versus "Bridge" Scenarios The Program in question applied only in the case of patients new to therapy. However, similar "bridge" programs may also be justifiable in situations where a patient is already taking a therapy, experiences a disruption in his or her insurance coverage as a result of a change in employment or insurer, and desires to maintain continuity of therapy while coverage under the new insurance plan is sorted out. From our perspective, these situations may be even more defensible under the usual risk factors identified by the OIG, inasmuch as the alternative would be a disruption to the patient's therapy.

Manufacturers and other stakeholders involved in the design and administration of such programs should carefully consider these and other factors unique to their products when evaluating such programs.

***

If you have further questions concerning Advisory Opinion 15-11 or similar product programs, please contact Joseph Metro, Jackie Godin, or any other Reed Smith attorney with whom you have worked.

1 The opinion is available at http://oig.hhs.gov/fraud/docs/advisoryopinions/2015/AdvOpn15-11.pdf.

2 These sanctions are generally provided under the civil monetary penalty provisions under sections 1128(a)(5) and 1128(a)(7) of the Social Security Act, and the exclusion authority under section 1128(b)(7) of the Social Security Act.

3 The approved indications and diseases are not disclosed in the Opinion.

4 The OIG noted that the requestors certified that they pay the Pharmacy a fair market value dispensing fee.

5 See Centers for Medicare & Medicaid Services, Medicare Prescription Drug Benefit Manual, chapter 6, section 30.2.5, chapter 18, section 40.2.

6 See Special Advisory Bulletin: Offering Gifts and Other Inducements to Beneficiaries (Aug. 2002), available at http://oig.hhs.gov/fraud/docs/alertsandbulletins/SABGiftsandInducements.pdf.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.